Novel therapeutics targeting IRAK4 based on protein degradation are being developed for the treatment of HS. It is therefore important to characterize IRAK4 expression in the skin and blood of patients with HS. Important to demonstrate how IRAK4 degraders differentiate from kinase inhibitors in their effect on IRAK4 protein levels to subsequently impact IL-1R/TLR biology.

Join for free to read